Cerevast Medical, Inc. news
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By treating the underlying cause of the disease as opposed to the symptoms, this therapy has the
The European Stroke Organization has chosen “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis” for the September 2021 “Paper of the Month”.
Stroke has published “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis”. This meta-analysis uses individual patient data from 7 different randomized controlled trials, including the CLOTBUST-ER trial, to show that
Therapeutic Advances in Neurological Disorders has published “Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke”. This paper presents a case study of the CLOTBUST-ER trial, showing that the “increasing implementation of endovascul
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By treating the underlying cause of the disease as opposed to the symptoms, this therapy has the
The results of the CLOTBUST-ER trial, the first phase 3 trial to assess the safety and efficacy of sonothrombolysis, have been published in the April 2019 edition of Lancet Neurology. Though the trial did not meet its primary endpoint, the article and
Cerevast Medical, Inc., a medical technology company that develops medical products for the treatment of neurologic disorders, has licensed several technologies from Arizona State University to be used in innovative post-stroke rehabilitation devices.